共查询到20条相似文献,搜索用时 31 毫秒
1.
目的 探讨非霍奇金淋巴瘤(NHL)患者在自体干细胞移植(ASCT)前后行18F-脱氧葡萄糖(FDG)符合线路显像对于预测患者无进展生存期(PFS)的价值,并将结果 与CT检查进行对比分析.方法 29例经病理检查证实的NHL患者在ASCT前后均进行18F-FDG符合线路显像与CT检查,ASCT后随访时间均>1年.分别计算18F-FDG符合线路显像与CT检查的阳性预测值(PPV)、阴性预测值(NPV)和准确性,采用X2检验比较两者的结果 ,并采用Kaplan-Meier生存分析法行PFS分析.结果 ASCT前,18F-FDG显像的PPV、NPV和准确性分别为85.7%(12/14)、73.3%(11/15)和79.3%(23/29),高于CT检查的55.6%(10/18),45.5%(5/11)和51.7%(15/29);而在ASCT后,18F-FDG显像的PPV、NPV和准确性分别为92.3%(12/13)、75.0%(12/16)和82.8%(24/29),也分别高于CT检查的62.5%(10/16),53.8%(7/13)和58.6%(17/29);18?F-FDG显像和CT两者评价准确性差异有统计学意义(X2值分别为4.884和4.077,P均<0.05).ASCT前后18F-FDG显像阴性与阳性病例的PFS差异也有统计学意义(X2值分别为15.839和20.219,P均<0.005),而同期CT检查的阴性与阳性病例PFS差异无统计学意义(X2=2.468,P=0.116).ASCT前后,18F-FDG显像阴性和阳性患者的1年无进展生存率分别为86.7%(13/15)、87.5%(14/16)和28.6%(4/14)、23.1%(3/13).结论 ASCT前后18F-FDG符合线路显像均具有预测NHL预后的价值,且均优于CT检查. 相似文献
2.
Seng Chuan Ong Heiko Sch?der Nancy Y Lee Snehal G Patel Diane Carlson Matthew Fury David G Pfister Jatin P Shah Steven M Larson Dennis H Kraus 《Journal of nuclear medicine》2008,49(4):532-540
For patients with locoregional advanced head and neck squamous cell carcinoma (HNSCC), concurrent chemoradiotherapy is a widely accepted treatment, but the need for subsequent neck dissection remains controversial. We investigated the clinical utility of 18F-FDG PET/CT in this setting. METHODS: In this Institutional Review Board (IRB)-approved and Health Insurance Portability and Accountability Act (HIPPA)-compliant retrospective study, we reviewed the records of patients with HNSCC who were treated by concurrent chemoradiation therapy between March 2002 and December 2004. Patients with lymph node metastases who underwent 18F-FDG PET/CT > or = 8 wk after the end of therapy were included. 18F-FDG PET/CT findings were validated by biopsy, histopathology of neck dissection specimens (n = 18), or clinical and imaging follow-up (median, 37 mo). RESULTS: Sixty-five patients with a total of 84 heminecks could be evaluated. 18F-FDG PET/CT (visual analysis) detected residual nodal disease with a sensitivity of 71%, a specificity of 89%, a positive predictive value (PPV) of 38%, a negative predictive value (NPV) of 97%, and an accuracy of 88%. Twenty-nine heminecks contained residual enlarged lymph nodes (diameter, > or =1.0 cm), but viable tumor was found in only 5 of them. 18F-FDG PET/CT was true-positive in 4 and false-positive in 6 heminecks, but the NPV was high at 94%. Fifty-five heminecks contained no residual enlarged nodes, and PET/CT was true-negative in 50 of these, yielding a specificity of 96% and an NPV of 98%. Lack of residual lymphadenopathy on CT had an NPV of 96%. Finally, normal 18F-FDG PET/CT excluded residual disease at the primary site with a specificity of 95%, an NPV of 97%, and an accuracy of 92%. CONCLUSION: In patients with HNSCC, normal 18F-FDG PET/CT after chemoradiotherapy has a high NPV and specificity for excluding residual locoregional disease. In patients without residual lymphadenopathy, neck dissection may be withheld safely. In patients with residual lymphadenopathy, a lack of abnormal 18F-FDG uptake in these nodes also excludes viable tumor with high certainty, but confirmation of these data in a prospective study may be necessary before negative 18F-FDG PET/CT may become the only, or at least most-decisive, criterion in the management of the neck after chemoradiotherapy. 相似文献
3.
Solid splenic masses: evaluation with 18F-FDG PET/CT. 总被引:4,自引:0,他引:4
Ur Metser Elka Miller Ada Kessler Hedva Lerman Gennady Lievshitz Ran Oren Einat Even-Sapir 《Journal of nuclear medicine》2005,46(1):52-59
Our objective was to assess the role of (18)F-FDG PET/CT in the evaluation of solid splenic masses in patients with a known malignancy and in incidentally found lesions in patients without known malignancy. METHODS: Two groups of patients were assessed: (a) 68 patients with known malignancy and a focal lesion on PET or a solid mass on CT portions of the PET/CT study; and (b) 20 patients with solid splenic masses on conventional imaging without known malignancy. The standard of reference was histology (n = 16) or imaging and clinical follow-up (n = 72). The lesion size, the presence of a single versus multiple splenic lesions, and the intensity of (18)F-FDG uptake expressed as a standardized uptake value (SUV) were recorded. The ratio of the SUV in the splenic lesion to the background normal splenic uptake was also calculated. These parameters were compared between benign and malignant lesions within each of the 2 groups of patients and between the 2 groups. RESULTS: The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of (18)F-FDG PET/CT in differentiating benign from malignant solid splenic lesions in patients with and without malignant disease were 100%, 100%, 100%, and 100% versus 100%, 83%, 80%, and 100%, respectively. In patients with known malignant disease, an SUV threshold of 2.3 correctly differentiated benign from malignant lesions with the sensitivity, specificity, PPV, and NPV of 100%, 100%, 100%, and 100%, respectively. In patients without known malignant disease, false-positive results were due to granulomatous diseases (n = 2). CONCLUSION: (18)F-FDG PET can reliably discriminate between benign and malignant solid splenic masses in patients with known (18)F-FDG-avid malignancy. It also appears to have a high NPV in patients with solid splenic masses, without known malignant disease. (18)F-FDG-avid splenic masses in patients without a known malignancy should be further evaluated as, in our series, 80% of them were malignant. 相似文献
4.
Role of (18)F-FDG dual-head gamma-camera coincidence imaging in recurrent or metastatic colorectal carcinoma. 总被引:7,自引:0,他引:7
Einat Even-Sapir Hedva Lerman Arie Figer Micha Rabau Gennady Livshitz Moshe Inbar Mordechai Gutman 《Journal of nuclear medicine》2002,43(5):603-609
(18)F-FDG PET has been shown to be of high diagnostic accuracy for the evaluation of recurrent colorectal cancer. However, the limited availability of PET scanners precludes (18)F-FDG assessment of many patients for whom the study is indicated. An alternative is the SPECT system in coincidence mode. The aim of this study was to determine the role of dual-head camera (18)F-FDG coincidence imaging (DHC (18)F-FDG) in patients with recurrent colorectal cancer. METHODS: Sixty-seven DHC (18)F-FDG studies were performed on 62 patients with suspected recurrent colorectal cancer. Reports of contemporary CT were available for the purpose of correlation for 61 of the studies. The final diagnosis of the imaging findings was based on histology or clinical and imaging follow-up of at least 6 mo. RESULTS: In lesion-based analysis, 103 tumor sites were suspected on DHC (18)F-FDG, CT, or colonoscopy. Ninety-three of them were found to be true tumor sites. For DHC (18)F-FDG, the sensitivity was 88%, specificity was 80%, positive predictive value (PPV) was 98%, negative predictive value (NPV) was 42%, and accuracy was 87%. For CT, the sensitivity was 63%, specificity was 10%, PPV was 85%, NPV was 3%, and accuracy was 57%. In patient-based analysis, DHC (18)F-FDG differentiated patients with recurrent cancer from disease-free patients with a sensitivity of 91%, specificity of 73%, PPV of 94%, NPV of 62%, and accuracy of 88%. DHC (18)F-FDG detected tumor sites in 12 (67%) of 18 patients with elevated carcinoembryonic antigen and negative CT findings. CONCLUSION: DHC (18)F-FDG is an adequate readily available technique for assessment of recurrent colorectal cancer and has a diagnostic accuracy better than that of CT. 相似文献
5.
Seng C Ong Heiko Sch?der Snehal G Patel Ida M Tabangay-Lim Indukala Doddamane Mithat G?nen Ashok R Shaha R Michael Tuttle Jatin P Shah Steven M Larson 《Journal of nuclear medicine》2007,48(4):501-507
Medullary thyroid carcinoma (MTC) is a rare endocrine tumor arising from the C-cells of the thyroid gland. Calcitonin is the principal serum tumor marker. A rising calcitonin level after total thyroidectomy for localized disease generally indicates residual, recurrent, or metastatic disease. The role of (18)F-FDG PET in MTC remains somewhat unclear. We reviewed our own experience with (18)F-FDG PET in postthyroidectomy MTC patients with elevated calcitonin. METHODS: From our database, we identified patients with suspected residual, recurrent, or metastatic MTC and elevated calcitonin who had been referred for (18)F-FDG PET between January 2000 and October 2005. (18)F-FDG PET findings were classified as positive or negative on the basis of visual interpretation of the scan. Standardized uptake values (SUVs) were also calculated. The (18)F-FDG PET findings were verified by histopathologic examination, when available, or other imaging studies and clinical follow-up. Any negative (18)F-FDG PET result was considered false-negative. RESULTS: Twenty-eight patients underwent a total of 38 (18)F-FDG PET studies. Calcitonin levels ranged from 106 to 541,000 pg/mL (median, 7,260 pg/mL). There were 23 true-positive, 1 false-positive, and 14 false-negative (18)F-FDG PET scans, yielding an overall sensitivity of 62%. There was no true-positive finding when calcitonin levels were below 509 pg/mL (n = 5). Using an arbitrary cutoff of 1,000 pg/mL, we found that the sensitivity in scans with calcitonin levels greater than 1,000 pg/mL increased to 78% (21/27; 95% confidence interval, 58%-91%). The mean SUV of all lesions with (18)F-FDG uptake was 5.3 +/- 3.2 (range, 2.0-15.9). Among the 14 patients with false-negative (18)F-FDG PET findings, 8 had concurrent anatomic imaging studies and only 2 of these had positive findings. CONCLUSION: (18)F-FDG PET can detect residual, recurrent, or metastatic MTC with a reasonable sensitivity of 78% when the calcitonin level is above 1,000 pg/mL but appears of limited use if the calcitonin level is below 500 pg/mL. 相似文献
6.
7.
Evaluation of the clinical value of combination of 99mTc-MIBI myocardial SPECT and 18F-FDG PET in assessing myocardial viability. 总被引:3,自引:0,他引:3
PURPOSE: To evaluate the value of 18F-FDG PET metabolic imaging and 99mTc-MIBI SPECT in the identification of myocardial viability in patients with previous myocardial infarction and left ventricular dysfunction. METHODS: 18F-FDG PET (made in China) and 99mTc-MIBI SPECT were performed in 60 patients (pts) (age 54+/-9 yr) with myocardial infarction before revascularization. Before and after revascularization, LVEF and wall motion were measured with echocardiography in 36 pts (Group A), and myocardial perfusion was evaluated in 24 pts (Group B). RESULTS: According to the interpretation of perfusion and metabolic images, myocardial segments were classified into mismatch (MM): reduced myocardial perfusion and normal FDG uptake or match (M): reduced perfusion and FDG uptake. Out of 264 segments with hypoperfusion, 145 (54.9%) were MM, suggesting viable myocardium (G-A1 and G-B1), 119 (45.1%) were M, suggesting necrosis (G-A2 and G-B2). After revascularization, LVEF was increased in G-A1 (49+/-15% vs. 59+/-7%, p<0.05), and in G-B1 (50+/-8% vs. 59+/-12%, p<0.05), but was not improved in G-A2 and G-B2. LVEDD was decreased in G-A1 and G-B1 (p<0.05) and was unchanged in G-A2 and G-B2. The positive predictive value (PPV) of FDG PET for improvement of regional wall motion after revascularization was 88%, and the negative predictive value (NPV) was 72.6%. The PPV for improvement of perfusion was 84.1%, NPV was 85%, and accuracy was 84.4%. CONCLUSION: 18F-FDG imaging with Chinese PET has clinical value for assessing myocardial viability and identifying patients who will benefit from revascularization. 相似文献
8.
Le Roux PY Gastinne T Le Gouill S Nowak E Bodet-Milin C Querellou S Mahe B Dubruille V Blin N Salaun PY Bodere-Kraeber F 《European journal of nuclear medicine and molecular imaging》2011,38(6):1064-1071
Purpose
Interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) has shown to be an accurate predictor of prognosis in Hodgkin??s lymphoma (HL). However, FDG PET response criteria are a matter of ongoing debate. The aim of this study was to confirm the prognostic value of interim PET/CT in HL patients treated with an interim response-adapted strategy and to compare the respective performances of different published criteria.Methods
Newly diagnosed patients with HL underwent interim PET/CT after four courses of Adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). The treatment strategy was adapted according to prognostic factors at diagnosis and interim PET/CT and CT results. PET images were prospectively interpreted visually: a negative result was defined as no residual uptake above local background. All other findings were considered as positive. Retrospectively, interim PET/CT was analysed according to International Harmonization Project (IHP), Gallamini and London criteriaResults
The analysis included 90 patients; 6 of 31 patients with positive interim PET/CT and 7 of 59 patients with negative interim result presented treatment failure. The negative predictive value (NPV) and positive predictive value (PPV) for predicting 2-year progression-free survival (PFS) was 95 and 16%, respectively. With the other criteria, NPV remained very high (from 95 to 96%). The PPV increased from 19 to 45% according to the threshold used. Interim PET/CT was significantly correlated with PFS with Gallamini (p?=?0.01) and London criteria (p?<?0.0001).Conclusion
Our study confirms the high NPV of interim PET/CT for predicting treatment outcome in HL and a probably better prognostic value using a higher threshold for positivity even after four cycles of chemotherapy as used in Gallamini and London criteria. 相似文献9.
Punit Sharma Bangkim Chandra Khangembam K. C. Sudhir Suman Harmandeep Singh Sishir Rastogi Shah Alam Khan Sameer Bakhshi Sanjay Thulkar Chandrasekhar Bal Arun Malhotra Rakesh Kumar 《European journal of nuclear medicine and molecular imaging》2013,40(7):1036-1043
Purpose
To evaluate the diagnostic accuracy of 18F-FDG PET/CT for detecting recurrence in patients with primary skeletal Ewing sarcoma.Methods
We retrospectively analysed data from 53 patients (age 20.1?±?10.5 years, 39 male) who had undergone 71 18F-FDG PET/CT studies for suspected recurrence (52 studies) or for routine follow-up (19 studies) after primary therapy of skeletal Ewing sarcoma. 18F-FDG PET/CT studies were evaluated qualitatively and quantitatively (maximum standardized uptake value, SUVmax) by two nuclear medicine physicians in consensus. Sensitivity, specificity, predictive values and accuracy were calculated on per study basis. Clinical/imaging follow-up (minimum 6 months) and/or histopathology (when available) were taken as the reference standard.Results
Of the total of 71 18F-FDG PET/CT studies, 42 (59.1 %) were positive for recurrence and 29 (40.9 %) were negative for recurrence. Local recurrence was most common (38 studies) followed by bone metastasis (9 studies), and node and lung metastasis (2 studies each). Of the 71 studies, 38 were true-positive, 27 were true-negative, 4 were false-positive and 2 were false-negative. Overall per study based sensitivity was 95 %, specificity was 87 %, PPV was 90 %, NPV was 93 % and accuracy was 91.5 %. No significant difference was found in the accuracy of PET/CT between the suspected recurrence group and the routine follow-up group (94 % vs. 84 %; P?=?0.390). Overall mean lesion SUVmax was 7.8?±?4.1 (range 1.9–17.2). No site-based difference was found in SUVmax.Conclusion
18F-FDG PET/CT demonstrates high diagnostic accuracy for detecting recurrence in patients with primary skeletal Ewing sarcoma, when it is suspected (clinically or on imaging) or during routine follow-up. 相似文献10.
Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. 总被引:12,自引:0,他引:12
Duska Vranjesevic Jean Emmanuel Filmont Joubin Meta Daniel H Silverman Michael E Phelps Jyotsna Rao Peter E Valk Johannes Czernin 《Journal of nuclear medicine》2002,43(3):325-329
This study was conducted to determine the ability of (18)F-FDG PET and conventional imaging (CI) to predict the outcomes in breast cancer patients who have previously undergone primary treatment. METHODS: The study population consisted of 61 female patients (median age, 54 y; range, 32--91 y) who were reevaluated with (18)F-FDG PET and CI after treatment. The median interval between the last treatment and PET was 0.4 y (range, 0--16 y). PET was performed within 3 mo of CI (median interval, 25 d; range, 2--84 d). To determine the independent impact of PET on outcome, PET images were reinterpreted in a blind fashion. Availability of clinical information after PET scanning (21 plus minus 12 mo) was required for study inclusion. Study endpoints were clinical evidence of progression of disease or death. RESULTS: Of 61 patients, 19 (31.1%) had no clinical evidence and 38 (62.3%) had evidence of residual or recurrent disease by the end of follow-up. Four patients (6.6%) had died. The positive and negative predictive values (PPV and NPV, respectively) of PET were 93% and 84%, respectively. CI yielded a PPV of 85% and an NPV of 59%. The prognostic accuracy of single whole-body PET was superior to that of multiple procedures with CI (90% vs. 75%; P < 0.05). Kaplan--Meier estimates of disease-free survival in patients with negative PET findings compared with those with positive PET findings revealed a significant difference between the 2 curves (log-rank test = 0.001). Kaplan--Meier estimates of disease-free survival stratified by CI results showed a marginally significant difference between CI-positive and CI-negative patients (log-rank test = 0.04). CONCLUSION: FDG PET can be used to improve prediction of the clinical outcome of previously treated breast cancer patients relative to what is achievable through CI alone. 相似文献
11.
11C-胆碱与18F-FDG双时相PET显像在孤立性肺结节鉴别诊断中的应用 总被引:4,自引:1,他引:3
目的 比较^11C-胆碱、18F-脱氧葡萄糖(FDG)和^18F-FDG双时相PET显像对鉴别肺部孤立性结节良恶性的价值。方法16例临床疑为肺肿瘤的患者进行^18F-FDGPET显像(注药后1h显像,2h后行延迟显像)、^11C-胆碱PET显像(3d内,于注药后10min进行)。图像判断以标准摄取值(SUV)作为半定量指标,异常放射性浓聚灶以SUV〉2.5为葡萄糖代谢增高,^18F-FDG延迟显像SUV上升≥10%为恶性病变(阳性),如下降或升高〈10%为良性病变(阴性);^11C-胆碱异常摄取灶以SUV〉2.0为阳性。所有病例进行随访,以显像诊断是否符合病理检查结果作为判断标准。结果病理检查结果证实12例肺癌,3例结核,1例结节病。^11C-胆碱PET显像确诊了12例肿瘤中的ll例,而^18F-FDG PET显像确诊10例(10/12例),双时相^18F-FDG PET显像确诊11例。4例良性病变者,^11C-胆碱PET显像能较好鉴别;而^18F-FDG PET显像2例假阳性,结合延迟显像仅1例假阳性。结论 ^11C-胆碱和^18F-FDG PET显像均能较好地鉴别肺部良恶性肿瘤。但^11C-胆碱和双时相^18F-FDGPET显像优于常规^18F-FDGPET显像,三者联合能提高对肺部病变的诊断效率。 相似文献
12.
K. Kubiessa S. Purz M. Gawlitza A. Kühn J. Fuchs K. G. Steinhoff A. Boehm O. Sabri R. Kluge T. Kahn P. Stumpp 《European journal of nuclear medicine and molecular imaging》2014,41(4):639-648
Purpose
The aim of this study was to evaluate the diagnostic capability of simultaneous 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/MRI compared to 18F-FDG PET/CT as well as their single components in head and neck cancer patients.Methods
In a prospective study 17 patients underwent 18F-FDG PET/CT for staging or follow-up and an additional 18F-FDG PET/MRI scan with whole-body imaging and dedicated examination of the neck. MRI, CT and PET images as well as PET/MRI and PET/CT examinations were evaluated independently and in a blinded fashion by two reader groups. Results were compared with the reference standard (final diagnosis determined in consensus using all available data including histology and follow-up). Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated.Results
A total of 23 malignant tumours were found with the reference standard. PET/CT showed a sensitivity of 82.7 %, a specificity of 87.3 %, a PPV of 73.2 % and a NPV of 92.4 %. Corresponding values for PET/MRI were 80.5, 88.2, 75.6 and 92.5 %. No statistically significant difference in diagnostic capability could be found between PET/CT and PET/MRI. Evaluation of the PET part from PET/CT revealed highest sensitivity of 95.7 %, and MRI showed best specificity of 96.4 %. There was a high inter-rater agreement in all modalities (Cohen’s kappa 0.61–0.82).Conclusion
PET/MRI of patients with head and neck cancer yielded good diagnostic capability, similar to PET/CT. Further studies on larger cohorts to prove these first results seem justified. 相似文献13.
目的探讨^18F-FDGPET/CT显像在鼻咽癌首次分期、再分期及疗效监测中的临床应用价值。方法通过分析86例鼻咽癌患者^18F-FDGPET/CT扫描结果,结合其他临床资料和随访结果,计算^18F-FDGPET/CT显像的准确性、特异性、灵敏度、阳性预测值与阴性预测值,并与CT、MRI进行比较。结果^18F-FDGPET/CT与CT、MRI诊断鼻咽癌的准确率、敏感性、特异性、阳性预测值与阴性预测值的差异均有统计学意义(P〈0.05)。依据^18F-FDGPET/CT结果,改变了4例首次分期、14例再分期的临床诊断和22例患者的治疗方案。结论与CT、MRI相比,^18F-FDGPET/CT显像对鼻咽癌的临床分期及疗效监测具有更重要价值。 相似文献
14.
Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. 总被引:5,自引:0,他引:5
Christian Guay Mariette Lépine Jean Verreault Fran?ois Bénard 《Journal of nuclear medicine》2003,44(8):1225-1231
Detection of relapse after completion of therapy in patients with Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL) constitutes an important challenge in modern medical imaging. An accurate assessment of the presence of residual disease is essential to determine which patients would benefit from additional therapy. The objective of this study was to assess the diagnostic accuracy of (18)F-FDG PET in detecting residual disease or relapse during the posttherapy period in patients with HD in comparison with CT. We also established different predictive values for (18)F-FDG PET according to the time interval between the end of therapy and the PET study. METHODS: Forty-eight patients with HD underwent (18)F-FDG PET after the completion of chemotherapy (median, 58 d) between March 1999 and April 2002. Disease-free intervals and proportions were calculated using the Kaplan-Meier method. Standardized uptake values of the most active lesion in each patient with a positive study were also measured. PET and CT results were compared with clinical follow-up, with relapse being defined by a positive biopsy or the introduction of a second-line treatment. RESULTS: Thirty-four patients were still disease-free during a mean follow-up of 605 d. Fourteen patients relapsed during a mean follow-up of 197 d. The sensitivity and specificity of (18)F-FDG PET to predict relapse were 79% and 97%, respectively. The positive predictive value and the negative predictive value were both equal to 92%. The diagnostic accuracy of (18)F-FDG PET (92%) was significantly higher than the accuracy of CT (56%) (P < 0.0005). Patients with positive (18)F-FDG PET also had a far shorter median disease-free interval (79 d) than those with positive CT (disease-free proportion of 52% at 1,143 d) (P = 0.0046). The 3 cases of false-negative (18)F-FDG PET studies that we observed occurred in patients who underwent their PET study within the first 49 d after the end of chemotherapy. CONCLUSION: Positive (18)F-FDG PET after the end of therapy in HD patients is a strong predictor of relapse. A negative PET study is also an excellent predictor of good prognosis. The diagnostic accuracy of (18)F-FDG PET to assess the presence of residual disease after therapy is superior to that of CT. 相似文献
15.
F Slevin M Subesinghe S Ramasamy M Sen A F Scarsbrook R J D Prestwich 《The British journal of radiology》2015,88(1052)
Objective:
To assess the accuracy of a 4-month post-(chemo)radiotherapy 18-fludeoxyglucose (18F-FDG) positron emission tomography (PET)-CT for head and neck squamous cell carcinoma (HNSCC).Methods:
105 patients who underwent a baseline and response assessment 18F-FDG PET-CT scan between 2008 and April 2013 were identified. 18F-FDG PET-CT outcomes were analysed with reference to clinicopathological outcomes.Results:
79 of 105 (75%) 18F-FDG PET-CT scans demonstrated a complete metabolic response; 19 of 101 (19%) for assessable primary tumours were positive; and 19 of 93 (20%) for patients with nodal disease were equivocal (n = 10) or positive (n = 9). The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for primary and nodal disease were 90%, 89%, 47%, 99% and 91%, 89%, 53% and 99%, respectively. Eight of nine patients with a positive nodal response scan had clinicopathological evidence of residual nodal disease (PPV, 89%). 2 of 10 patients with equivocal nodal responses had clinicopathological evidence of residual nodal disease (PPV, 20%).Conclusion:
18F-FDG PET-CT 4 months post treatment has a very high NPV. A positive 18F-FDG PET-CT has a high PPV for residual nodal disease. By contrast, patients who have an equivocal nodal response have a low PPV.Advances in knowledge:
Response assessment 18F-FDG PET-CT is a valuable tool in guiding the selective use of neck dissection following (chemo)radiotherapy for HNSCC. An equivocal lymph node response has a limited predictive value for persistent disease, and optimal management remains a clinical challenge. 相似文献16.
Omar Ahmad Hassanien Hanan Mohamad Saleh Elahwal Manar Hussein Abdelsattar Ekhlas Abdelmonem Ibrahem Nasr Shaban 《The Egyptian Journal of Radiology and Nuclear Medicine》2018,49(2):467-473
Purpose
This study aimed at assessment of the role of (PET/CT) in lymphoma after completion of therapy to differentiate post-treatment fibrosis from residual viable tumor and being familiar with the limitations and interpretative pitfalls of PET/CT.Method and materials
The present study was performed on 50 patients(27 males and 23 females).18F-FDG was injected IV one hour before performing the study. Contrast enhanced CT was performed followed by PET.Results
After the end of therapy; PET/CT revealed (38%) of cases showed a partial regression, (28%) of cases showed a progressive disease, (22%) of cases with complete metabolic disease remission, (8%) of cases showed a stationary disease and the remaining (4%) of cases showed mixed response to therapy. CT only agreed with PET/CT in 76% of the cases. Some physiologic uptake often occurs after treatment in (4%) of patients. PET/CT has 100% sensitivity,68.75 % specificity, 87.17% PPV, 100% NPV and 90% accuracy in treatment response of lymphoma; compared to 94.1% sensitivity and 50% specificity, 80% PPV, 80% NPV and 80% accuracy for CECT.Conclusion
PET/CT is a multimodality technique that can accurately monitor the treatment response of lymphoma. It can differentiate residual mass containing viable tumor from post treatment fibrosis. 相似文献17.
18F-FDG PET/CT显像诊断心包恶性病变的价值 总被引:1,自引:0,他引:1
目的 评价18F-脱氧葡萄糖(FDG)PET/CT对心包恶性病变的诊断价值.方法 对23例心包积液患者进行18F-FDG PET/CT显像,并采用两独立样本非参数检验分析良恶性病灶最大标准摄取值(SUVmax)差异有无统计学意义.结果 经病理检查证实恶性心包积液14例,良性心包积液9例.1例PET/CT假阴性,2例PET/CT假阳性.18F-FDG PET/CT鉴别诊断良恶性心包积液的灵敏度、特异性、准确性、阳性预测值、阴性预测值分别为92.9%(13/14)、7/9、87.0%(20/23)、86.7%(13/15)和7/8.良、恶性病变的SUVmax中位值分别为2.2和6.0,两者间比较差异有统计学意义(z=-3.279,P=0.001).结论 18F-FDG PET/CT是评价心包恶性病变较好的无创性手段,对良恶性心包积液的诊断与鉴别诊断有一定临床价值. 相似文献
18.
Hyun Jeong Kim Arthur Cho Mijin Yun Young Tae Kim Won Jun Kang 《Annals of nuclear medicine》2016,30(2):104-113
Objective
Endometrial cancer is the most frequent cancer occurring in the female genital tract in the Western countries. Because surgical staging is currently the standard, noninvasive techniques that accurately identify lymph node (LN) metastases would be beneficial by reducing costs and complications. The purpose of our study is to compare the diagnostic accuracy of 2-[18F]fluoro-2-deoxy-d-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) with that of magnetic resonance imaging (MRI) for detecting LN metastases in the preoperative staging of endometrial cancer.Methods
Two hundred eighty-seven consecutive patients with endometrial cancer underwent preoperative PET/CT and MRI for staging. The malignancy criteria for LNs were a short diameter of 1 cm or more by MRI and focally increased 18F-FDG uptake by PET/CT. After evaluating PET/CT and MRI separately, morphologic and functional image findings were compared with the histological findings regarding LN metastasis for all patients. PET/CT and MRI images were classified on the basis of histological findings as true-positive, true-negative, false-positive, or false-negative. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were calculated.Results
Histologic examination revealed LN metastases in 51 patients (17.8 %). The maximal standardized uptake values (SUVmax) of the primary lesions by PET/CT ranged from 1.4 to 37.7, with a mean value of 9.3, whereas those of the metastatic LNs ranged from 2.0 to 22.5 with a mean of 7.3. On a per-patient basis, node staging resulted in sensitivities of 70.0 % with 18F-FDG PET/CT and 34.0 % with MRI, and specificities of 95.4 % with PET/CT and 95.0 % with MRI. The NPV of PET/CT was 94.3 %, and that of MRI was 87.2 %. On a lesion base analysis, sensitivity of PET/CT was 79.4 % while that of MRI was 51.6 %. In detecting distant metastasis, the sensitivity, specificity, accuracy, PPV, and NPV of PET/CT were 92.9, 98.9, 98.6, 81.3, and 99.6 %, respectively.Conclusion
Diagnostic performance of FDG PET/CT was better than MRI for detecting metastatic lymph nodes in patients with endometrial cancer both by patient basis and lesion basis analyses. Due to high NPV, FDG PET-CT could aid in selecting candidates for lymphadenectomy.19.
Castellucci P Perrone AM Picchio M Ghi T Farsad M Nanni C Messa C Meriggiola MC Pelusi G Al-Nahhas A Rubello D Fazio F Fanti S 《Nuclear medicine communications》2007,28(8):589-595
AIMS: To (a) assess the accuracy of 18F-FDG PET/CT in distinguishing malignant from benign pelvic lesions, compared to transvaginal ultrasonography (TVUS) and (b) to establish the role of whole-body 18F-FDG PET/CT, compared to contrast enhanced computed tomography (CT), in staging patients with ovarian cancer. PATIENTS: Fifty consecutive patients with a pelvic lesion, already scheduled for surgery on the basis of physical examination, TVUS, and serum Ca125 levels, were enrolled in the study. Patients' age ranged between 23 and 89 years (mean 64). All patients underwent TVUS including a colour Doppler study followed by a thorax and abdominal CT scan, and whole-body 18F-FDG PET/CT within 2 weeks prior to surgery. Histological findings obtained at surgery were taken as the 'gold standard' to compare 18F-FDG PET/CT and TVUS, and 18F-FDG PET/CT vs. CT. When tissue analysis showed ovarian cancer, the accuracy of 18F-FDG PET/CT and CT were compared for the purpose of obtaining a precise staging. RESULTS: At surgery, the ovarian lesions were malignant in 32/50 patients (64%) and benign in the remaining 18/50 patients (36%). The sensitivity, specificity, NPV, PPV and accuracy of 18F-FDG PET/CT were 87%, 100%, 81%, 100% and 92%, respectively, compared with 90%, 61%, 78%, 80% and 80%, respectively, for TVUS. In staging ovarian cancer, 18F-FDG PET/CT results were concordant with final pathological staging in 22/32 (69%) patients while CT results were concordant in 17/32 (53%) patients. CT incorrectly down-staged four out of six stage IV patients by missing distant metastasis in the liver, pleura, mediastinum, and in left supraclavicular lymph nodes, which were correctly detected by 18F-FDG PET/CT. CONCLUSION: PET/CT with 18F-FDG provides additional value to TVUS for the differential diagnosis of benign from malignant pelvic lesions, and to CT for the staging of ovarian cancer patients. 相似文献
20.
Suk Hyun Lee Changhwan Sung Hyo Sang Lee Hee-young Yoon Soo-Jong Kim Jungsu S. Oh Jin Woo Song Mi Young Kim Jin-Sook Ryu 《Annals of nuclear medicine》2018,32(7):492-498